Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB016 vs Entyvio in moderate to severe active ulcerative colitis
MOH_2023-08-22_012893Phase 3Not yet recruiting
- Sponsor
- Polpharma Biologics
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in autoimmune colitis (2 arms), sponsored by Polpharma Biologics. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2023-08-22_012893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-22_012893.